Roth Capital downgrades Barrier Therapeutics (BTRX) to Hold from Buy
More News related to BTRX
- Agile Therapeutics Appoints Industry Expert, Al Altomari, as Chairman of Its Board of Directors
- FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
- Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc.
- Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc.
- Stiefel Laboratories Announces Expiration of Waiting Period to Acquire Barrier (BTRX)
Roth Capital downgrades Barrier Therapeutics (Nasdaq: BTRX) from Buy to Hold on acquisition news.
Barrier Therapeutics, Inc. (Barrier) is a pharmaceutical company focused on the development and commercialization of pharmaceutical products in the field of dermatology.
Related Categories
DowngradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
